2,490 results found

In January and February 2026, Health Canada released the Quarterly Report for Q2 2025-2026 (July through September 2025) and for Q3 2025-2026 (October through December 2025).

As previously reported, on July 12, 2018, Health Canada had published "Guidance on Notifying Health Canada of Foreign Actions – Guidance Document for Industry".

The Therapeutic Products Directorate (TPD), the Biologic and Radiopharmaceutical Drugs Directorate (BRDD), and the Natural and Non-Prescription Health Products Directorate (NNHPD) ...

On June 12, the Advisory Council on the Implementation of National Pharmacare released its final report which recommends that Canada implement a universa

In March 2023, the Minister of Health announced the National Strategy for Drugs for Rare Diseases, which has as its objective to increase access to, and affordability of, effective drugs for rare diseases...

On December 11, 2017, Health Canada announced a guidance document clarifying the requirements for drug submissions and applications to be processed under the administrative pathway.

The Patented Medicine Prices Review Board (PMPRB) has advised that the new Guidelines will not be implemented on January 1, 2023, and that the Interim Guidance issued by the...

On April 2, 2020, the Patented Medicine Prices Review Board (PMPRB) published a message from the Chairperson regarding the results of its consultation on the draft Guidelines operationalizing the...

Following its Phase 2 Consultations, on December 19, 2025, the Patented Medicine Prices Review Board (PMPRB) released its new Draft Guidelines and accompanying Overview.

On February 6, 2018, the Patented Medicine Prices Review Board (PMPRB) announced the publication of the most recent edition of its series of reports on generic drug pricing.

On January 5, 2022, amendments came into force amending the Food and Drug Regulations to allow practitioners to request access to restricted drugs through the Special Access Program (SAP)...

As previously reported, the Federal Court of Appeal (FCA) dismissed Apotex's appeal of a judicial review decision of the Therapeutic Products Directorate (TPD) ...

The Canadian Intellectual Property Office (CIPO) will be launching a new online portal for patent services, MyCIPO Patents, on July 15, 2024.

While the Court of Appeal held that the Federal Court erred in its identification of the inventive concept, it upheld the finding that the patent was obvious.

The Federal Court of Appeal affirmed that, under the Patent Act, a successful patentee always has a right to its damages, and only it has the right to elect an accounting of profits, subject to the court's discretion.

On January 29, 2020, Bill C-4, which addresses some of the changes required under the Agreement between Canada, the U.S. and Mexico (USMCA), was introduced in the House of...

The Supreme Court of Canada denied leave to appeal to Philip Morris from the Federal Court of Appeal's decision in Marlboro Canada Limited, Imperial Tobacco Canada Limited v. Phillips Morris Products S.A., Rothmans, Benson & Hedges Inc., 2012 FCA 201.

Jill Tonus contributed the sole legal paper, Legal Issues Regarding Oral Histories. Jill's paper can be found on page 98 of the reader.